ArticleOncology reports2018
Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera.
Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- The Clinical Application of Combined Ultrasound, Mammography, and Tumor Markers in Screening Breast Cancer among High-Risk Women.Computational and mathematical methods in medicine · 2022Trial
- Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay.Breast cancer research and treatment · 2025Article
- Glycosylation: mechanisms, biological functions and clinical implications.Signal transduction and targeted therapy · 2024Review
- Decoding the glycoproteome: a new frontier for biomarker discovery in cancer.Journal of hematology & oncology · 2024Review
- Review
- Proteinase K-pretreated ConA-based ELISA assay: a novel urine LAM detection strategy for TB diagnosis.Frontiers in microbiology · 2023Article
- Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.Exploration of targeted anti-tumor therapy · 2023Review
- Primary breast cancer biomarkers based on glycosylation and extracellular vesicles detected from human serum.Cancer reports (Hoboken, N.J.) · 2022Article
- Investigation of the Anticancer Effect ofMolecules (Basel, Switzerland) · 2022Article
- Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study.Cancer cell international · 2022Review
- Identification of glycogene signature as a tool to predict the clinical outcome and immunotherapy response in breast cancer.Frontiers in oncology · 2022Article
- Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine.Frontiers in endocrinology · 2022Review
- Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients.Scientific reports · 2021Article
- A Diagnostic Analysis Workflow to Optimal Multiple Tumor Markers to Predict the Nonmetastatic Breast Cancer from Breast Lumps.Journal of oncology · 2021Article
- Glycosylation of Trypanosoma cruzi TcI antigen reveals recognition by chagasic sera.Scientific reports · 2020Article
- Serum Levels and Glycosylation Changes of Alpha-1-Acid Glycoprotein According to Severity of Breast Cancer in Korean Women.Journal of microbiology and biotechnology · 2020Article
- Review
- Value of digital mammography in predicting lymphovascular invasion of breast cancer.BMC cancer · 2020Article
- Experimental Evidence on the Nature of the Antigen in the Direct Agglutination Test for Visceral Leishmaniasis.The American journal of tropical medicine and hygiene · 2020Article
- Diagnostic value of CA-153 and CYFRA 21-1 in predicting intraocular metastasis in patients with metastatic lung cancer.Cancer medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated serum CA15‑3 assessed by enzyme‑linked immunosorbent assay (ELISA) has been considered a diagnostic marker of breast cancer. However, accumulating data indicate that the current ELISA system for detecting CA15‑3, which targets the peptide backbone of CA15‑3, is not sufficiently sensitive to detect early or localized breast cancer. In the present study, we designed an antibody‑lectin sandwich assay detecting glycosylation of CA15‑3 in patients with breast cancer. Ιmmobilized anti‑CA15‑3 monoclonal antibody captures CA15‑3 in serum, and glycosylation of the CA15‑3 is detected with Concanavalin A (ConA) lectin, which preferentially bind high‑mannose N‑glycans. ConA provided the best signal for detecting serum CA15‑3 among 9 types of lectin, Since CA15‑3 is a heavily glycosylated protein, detecting the glycosylation of CA15‑3 should be a much more sensitive way to assess CA15‑3 than the current ELISA method. Linear responses were obtained in the anti‑CA15‑3 antibody‑ConA sandwich assay when sera were diluted up to 2000‑fold. This dilution factor is comparable with that of the current ELISA system which allows 50‑ to 100‑fold serum dilutions. The glycosylation level of CA15‑3 was found to increase with increasing breast cancer stage in the sandwich assay. The assay system appeared to efficiently discriminate breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. The antibody‑lectin sandwich assay shows promise as a new prospect for the early detection of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.